Generative AI, an offshoot of artificial intelligence, has quickly become a game-changer in biological research and healthcare applications. Leveraging deep learning algorithms and neural networks, this revolutionary technology produces data, models, and insights that deepen our understanding of complex biological systems. As such, its growth is experiencing dramatic expansion as research processes accelerate further while novel drug candidates emerge and healthcare solutions improve dramatically.

Global Generative AI in Biology Industry size is expected to be worth around USD 346.9 million by 2032 from USD 72.0 million in 2022, growing at a CAGR of 17.50 %. during the forecast period from 2023 to 2032.

Driving Factors:

Multiple forces contribute to the rapid proliferation of generative AI in biology. One key driver is the explosion in biological data relating to genomics, proteomics, and clinical issues which requires advanced computational methods for analysis and interpretation. Generative AI also facilitates rapid exploration of drug compound libraries reducing time and cost for drug discovery; in addition, the COVID-19 pandemic highlighted AI-driven approaches in vaccine development as well as epidemiological modeling which further propelled investment and interest in this area of science.